跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2013-003874-29-DE
EUCTR2013-003874-29-DE进行中（未招募）1 期

A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related genetic alterations

Clovis Oncology Italy s.r.l.0 个研究点目标入组 40 人开始时间: 2014年2月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
40
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1.Male or female patient aged = 18 years.
  • •2.Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC.
  • •3.Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting:
  • •Patient must be refractory to all appropriate and approved therapies.
  • •4.Any of the following tumor tissue based genetic alterations known prior to screening:
  • •FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRa amplification
  • •Any FGFR1, FGFR2, or FGFR3 fusion
  • •FGFR1, FGFR2, or FGFR3 activating mutation (see Appendix 5 for specific qualifying FGFR mutations)
  • •5.Availability of formalin fixed paraffin embedded (FFPE) tumor tissue sample sufficient for the central confirmation of the genetic alteration and exploratory analyses
  • •6.Documented progressive extra central nervous system (CNS) disease at the time of inclusion.
  • •7.At least one extra CNS measurable lesion according to RECIST 1.1 (with the last objective assessment no more than 4 weeks before the first dose of lucitanib). In addition, one prior measurable evaluation within a maximum of 3 months, if available, should be collected to assess tumor kinetics.
  • •8.At least one prior treatment line in the advanced/metastatic setting.
  • •9.Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • •10.Ability to take oral medication.
  • •11.Adequate bone marrow function: absolute neutrophil count (ANC) = 1.0 × 109/L, platelet counts = 100 × 109/L, and hemoglobin = 9 g/dL.
  • •12.Adequate renal function defined as: calculated clearance = 60 mL/minute (assessed with modification of diet in renal disease [MDRD] formula), proteinuria dipstick < 1+. If proteinuria dipstick = 1+, urinary protein over 24 hours should be < 1.0 g/24 hours.
  • •13.Adequate hepatic function defined as: aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 3 × under normal limit (UNL) (= 5 × UNL in case of liver metastasis); bilirubin < 1.5 × UNL; alkaline phosphatase (ALP) = 2.5 × UNL (= 5 × UNL in case of bone metastasis).
  • •14.LVEF = 50% evaluated by cardiac ultrasound (echocardiogram [ECHO]) or Multi Gated Acquisition Scan (MUGA).
  • •15.Negative serum pregnancy test during screening for women of child bearing potential within 7 days prior to the first dose of lucitanib
  • •16.For men and women of child-bearing potential, willingness to use an effective contraception method during the study and up to 6 months after the last dose is administered. Effective methods include the following: non-hormonal intrauterine device, barrier method (condoms, diaphragm) in combination with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are discouraged. Male patients whose sexual partners are women of child bearing potential must be willing to use effective contraception during the study and for 6 months after the end of treatment with lucitanib.
  • •17.Willingness and ability to give written informed consent and to comply with study procedures
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 24
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 16

排除标准

  • •1. Carcinoid history
  • •2. Known symptomatic CNS metastases not controlled by prior surgery or radiotherapy and/or low dose steroids.
  • •3. Active second malignancy; i.e., patient known to have potentially fatal cancer present for which he/she may be (but is not necessarily) currently receiving treatment .
  • •4. Chemotherapy within 6 months or bone marrow transplant (BMT) within 2 years prior to the first dose of lucitanib in patients with a history of cancer other than SCLC or NSCLC and with no current evidence of disease.
  • •5. Anti cancer treatment for lung cancer within 28 days or 5 half lives, whichever is longer, before the first dose of lucitanib.
  • •6. Investigational treatment within 28 days before the first dose of lucitanib
  • •7. Wide field radiotherapy = 4 weeks or limited field radiation for palliation = 2 weeks before the first dose of lucitanib.
  • •8. Tumors that are invading a major vessel
  • •9. NSCLC tumors abutting (adjacent and proximal) to a major vessel.
  • •10. History of major surgical procedure or significant trauma within 28 days prior to the first dose of lucitanib, or non study related minor surgical procedure within 14 days prior to the first dose of lucitanib.
  • •11. Ongoing AEs from surgery or prior anti cancer therapies, including radiation, targeted, or cytotoxic therapies without resolution of any Grade 2 or greater side effects to Grade = 1.
  • •12. History of gross hemoptysis within 3 months prior to first dose of lucitanib or history of hemoptysis = ½ teaspoon (2.5 mL) of blood per day for a day or more within 1 week prior to the first dose of lucitanib.
  • •13. History of coagulopathy or hemorrhagic disorders.
  • •14. History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 3 months prior to first dose of lucitanib
  • •15. Clinically significant non-healing wound, ulcer, or bone fracture.
  • •16. Uncontrolled hypertension (defined as systolic blood pressure ([SBP]) = 140 mmHg and/or diastolic blood pressure ([DBP]) = 90 mmHg) with optimized anti hypertensive therapy.
  • •The requirement for > 2 anti hypertensives to control hypertension at the time of enrolment is exclusionary.
  • •17. Cardiovascular disease or conditions, including:
  • •a. Congestive heart failure (New York Heart Association functional classification = 2) or requiring therapy.
  • •b. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, and/or stenting within 6 months before the first day of study drug administration.
  • •c. Ventricular and/or supra-ventricular arrhythmia requiring therapy.
  • •d. Conduction disturbance including QTC prolongation (defined as a QTC interval > 470 ms according to Fridericia’s correction as observed by the investigator) or other significant ECG abnormalities including 2nd degree atrioventricular (AV) block type II, 3rd degree AV block, or bradycardia (heart rate < 50 bpm); history of severe arrhythmia;, or history of familial arrhythmia [e.g., Wolff-Parkinson-White syndrome]).
  • •e. Risk factors for or concomitant treatment with medications known to prolong QTC interval and that are clearly associated with Torsades de Pointes (see Appendix 2).
  • •18. Patients with history of thromboticdisorders
  • •a. Any history of venous thrombotic events, deep vein thrombosis (with the exception of catheter related deep vein thrombosis), or pulmonary embolism within 6 months prior to the first dose of lucitanib.
  • •b. Any history of arterial thrombotic events, cerebrovascular a

研究者

发起方
Clovis Oncology Italy s.r.l.

相似试验

进行中（未招募）
1 期
A study to assess the effectiveness of the drug lucitanib in lung cancer patientsFGFR1-amplified squamous non-small cell lung cancer (NSCLC)MedDRA version: 16.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-003874-29-ITEOS S.p.A.40
进行中（未招募）
1 期
A study to assess the effectiveness of the drug lucitanib in lung cancer patients
EUCTR2013-003874-29-ESEOS S.p.A.18
进行中（未招募）
1 期
_Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting.MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864
EUCTR2015-000580-14-FRICANCER40
已完成
2 期
A phase II, open label, single arm study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L)EGFR mutation positive advanced or metastatic NSCLC
JPRN-UMIN000022076Clinical trial coordinating committee for WJOG8815L investigator-initiated multicenter clinical trial60
进行中（未招募）
1 期
Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age
EUCTR2011-000987-92-DEPharming Technologies B.V.20